Compare Kraft Heinz Co (KHC) vs TG Therapeutics Inc (TGTX) Price & Performance

Kraft Heinz (KHC) trades at $22.48, up 2.27% today, but remains in a bearish technical trend. The company reported a net loss of $5.85 billion in 2025 due to a significant impairment charge, though recent quarters have beaten EPS estimates. Operating cash flow remains strong at $4.46 billion, supporting a $0.40 dividend. News highlights focus on brand revitalization efforts, such as new Philadelphia cream cheese flavors, as part of a broader turnaround strategy.

The outlook is mixed: valuation metrics like P/B of 0.74 suggest potential undervaluation, but persistent net losses and high debt pose risks. Analyst sentiment is cautious with a consensus price target of $24.50. The stock's near-term direction hinges on successful execution of cost management and volume recovery initiatives amid competitive pressures.

TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.

The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.